Etanercept
| Evidence Level: L2 | Predicted Indications: 6 |
Table of Contents
Etanercept: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Etanercept (Enbrel) is a TNF receptor:Fc fusion protein whose established use — as reflected throughout the accompanying trial and literature evidence — is in TNF-α-driven inflammatory arthropathies such as rheumatoid arthritis. The TxGNN model predicts a possible role in rheumatoid vasculitis, but the supporting evidence is mixed and partly contradictory: of 6 clinical trials and 20 publications identified, several report etanercept-induced vasculitis rather than a therapeutic effect, and the only direct trial in a related vasculitis (Wegener’s granulomatosis / ANCA-associated vasculitis) did not confirm efficacy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis and related TNF-α-mediated inflammatory arthropathies (inferred from trial/literature context; no formal UK licence text available — see Data Gaps) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L2 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for etanercept is not available in this evidence pack (data gap, item DG002). Based on information embedded in the accompanying evidence, etanercept is a dimeric TNFR(p75):Fc fusion protein that neutralises tumour necrosis factor-alpha (TNF-α); its well-documented uses across the candidate set include rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis, all of which are TNF-α-driven inflammatory conditions.
Rheumatoid vasculitis is a severe extra-articular manifestation of rheumatoid arthritis, and TNF-α is also implicated in vascular endothelial inflammation, which is presumably why TxGNN scored this link highly. However, the directionality of the evidence in this case is uncertain and, in places, runs counter to the prediction: multiple case reports describe etanercept inducing cutaneous or renal vasculitis (nephropathy, accelerated nodulosis/vasculitis) rather than treating it, and a systematic review (PMID 33058033) notes only cautious support for biologics in rheumatoid vasculitis. The single directly relevant Phase 1/2 trial (NCT00001901, in Wegener’s granulomatosis/ANCA-associated vasculitis — a related but distinct vasculitis subtype) did not demonstrate clear efficacy and raised safety concerns, and a further review (PMID 28391344) questions whether TNF-α blockade has any role at all in ANCA-associated vasculitis.
This should therefore be treated as a mechanistically plausible but evidentially unresolved — and possibly reversed — signal, warranting safety-focused evaluation rather than an efficacy-first pathway.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00001901 | Phase 2 | Completed | 60 | Etanercept in Wegener’s granulomatosis (ANCA-associated vasculitis); efficacy not established, safety concerns raised |
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Perioperative immunosuppressant (incl. TNF inhibitor) management in rheumatology patients undergoing shoulder arthroplasty; not vasculitis-specific |
| NCT02590562 | N/A | Completed | 808 | Cross-sectional study of biologic DMARD treatment patterns in RA in China; not vasculitis-specific |
| NCT01557322 | N/A | Completed | 1,754 | Real-world RA treatment pathways comparing etanercept vs non-biologic therapy; not vasculitis-specific |
| NCT01579006 | N/A | Completed | 184 | Observational study of tocilizumab in RA; etanercept not the primary agent |
| NCT05696106 | N/A | Unknown | 750,000 | Risk of incident immune-mediated inflammatory diseases in patients on biologics/immunosuppressants for a single IMID |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33058033 | 2021 | Systematic Review | Clinical Rheumatology | Systematic review of biological therapy (including anti-TNF agents) in rheumatoid vasculitis |
| 28391344 | 2017 | Review | Nephrology Dialysis Transplantation | Questions whether TNF-α blockade has a role in ANCA-associated vasculitis and glomerulonephritis |
| 28123776 | 2017 | Cohort (BSRBR-RA) | RMD Open | TNF inhibitors carry a drug-specific risk of lupus-like and vasculitis-like events versus non-biologic DMARDs in RA |
| 15853915 | 2005 | Case Report/Mechanistic | Scandinavian Journal of Immunology | Describes immunologic mechanisms of cutaneous vasculitis associated with etanercept and infliximab |
| 31632872 | 2019 | Case Report | Cureus | Etanercept-associated nephropathy |
| 12209493 | 2002 | Case Report | Arthritis and Rheumatism | Accelerated nodulosis and vasculitis following etanercept therapy for RA |
| 11792895 | 2002 | Case Report | Rheumatology (Oxford) | Etanercept and infliximab associated with cutaneous vasculitis |
| 41327089 | 2025 | Case Report | BMC Nephrology | RA patient developing membranous nephropathy and ANCA-associated vasculitis successively |
| 31668853 | 2019 | Real-world Cohort | Biologicals | Efficacy and safety of original vs biosimilar (SB4) etanercept in a national RA cohort |
| 38931826 | 2024 | Population PK | Pharmaceutics | Population pharmacokinetic simulation of alternative dosing for etanercept/adalimumab biosimilars in RA |
UK Market Information
No UK marketing authorisations are currently on record for etanercept in this dataset (total licences: 0; market status: Not Marketed). This should be verified against the current MHRA product register and BNF, as the absence of a licence record here reflects a data gap rather than a confirmed regulatory position.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: the literature evidence above independently flags a recurring safety signal — etanercept-associated cutaneous and renal vasculitis, nodulosis, and lupus/vasculitis-like events — that is directly relevant to evaluating this predicted indication and should be weighed alongside the missing structured safety data (see Data Gap DG001, below).
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score reflects a plausible shared TNF-α mechanism, but the clinical trial and literature evidence do not consistently support a therapeutic effect in rheumatoid vasculitis — several sources instead document etanercept as a potential cause of vasculitis, and the only direct trial in a related vasculitis did not confirm efficacy. This evidentiary direction conflict means the candidate should not proceed on efficacy grounds without further clarification.
To proceed, the following is needed:
- Resolution of the blocking data gap (DG001): TFDA/MHRA SmPC warnings and contraindications, required before any S1 safety screening can be completed
- Etanercept mechanism of action data (DG002), to properly assess mechanistic plausibility versus the observed adverse vasculitis signal
- Clarification of disease taxonomy — whether “rheumatoid vasculitis” and “ANCA-associated vasculitis” (as tested in NCT00001901) should be treated as the same target for evaluation purposes
- A dedicated efficacy assessment (ideally a controlled trial) in rheumatoid vasculitis specifically, given that current evidence is observational, case-report-level, or drawn from an unrelated vasculitis subtype
- UK licensing and market-status verification against the current MHRA register
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.